Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~11 mi. (Concord, North Carolina, +744 more cities)

Atrium Health Cabarrus/LCI-Concord

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~11 mi. (Concord, North Carolina, +356 more cities)

Carolinas Medical Center Northeast

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

~11 mi. (Concord, North Carolina, +664 more cities)

Atrium Health Cabarrus/LCI-Concord

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

~11 mi. (Concord, North Carolina, +240 more cities)

Atrium Health Cabarrus/LCI-Concord

Endometrial Adenocarcinoma, +5 more conditions

carboplatin, +2 more drugs

chemotherapy, +1 more type

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

~11 mi. (Concord, North Carolina, +656 more cities)

Atrium Health Cabarrus/LCI-Concord

Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers

Colon Adenocarcinoma, +1 more condition

atezolizumab, +3 more drugs

chemotherapy, +1 more type

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

~11 mi. (Concord, North Carolina, +497 more cities)

Atrium Health Cabarrus/LCI-Concord

HER2 Positive

Breast Adenocarcinoma

atezolizumab, +4 more drugs

chemotherapy, +2 more types

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

~11 mi. (Concord, North Carolina, +235 more cities)

Atrium Health Cabarrus/LCI-Concord

Prostate Adenocarcinoma

abiraterone, +9 more drugs

hormone therapy, +2 more types

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

~11 mi. (Concord, North Carolina, +255 more cities)

Atrium Health Cabarrus/LCI-Concord

CDKN2A Overexpression, +1 more biomarker

Oropharyngeal Squamous Cell Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

~11 mi. (Concord, North Carolina, +405 more cities)

Atrium Health Cabarrus/LCI-Concord

Multiple Myeloma

daratumumab/hyaluronidase, +1 more drug

chemotherapy, +2 more types

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

~11 mi. (Concord, North Carolina, +224 more cities)

Atrium Health Cabarrus/LCI-Concord

HPV Negative

Hypopharyngeal Carcinoma, +3 more conditions

atezolizumab, +4 more drugs

chemotherapy, +3 more types

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

~11 mi. (Concord, North Carolina, +197 more cities)

Atrium Health Cabarrus/LCI-Concord

CCND1 Expression, +4 more biomarkers

Mantle Cell Lymphoma

autologous hematopoietic stem cell transplantation, +2 more drugs

cellular therapy, +2 more types

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

~11 mi. (Concord, North Carolina, +822 more cities)

Atrium Health Cabarrus/LCI-Concord

ER Negative, +2 more biomarkers

Invasive Breast Carcinoma

carboplatin, +3 more drugs

chemotherapy